Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shuo Ma & Leonidas C. Platanias. (2018) Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?. Expert Opinion on Pharmacotherapy 19:11, pages 1171-1175.
Read now
Read now
James B. Johnston. (2015) Enhancing monoclonal antibody activity in chronic lymphocytic leukemia. Leukemia & Lymphoma 56:8, pages 2231-2232.
Read now
Read now
Articles from other publishers (16)
Emma J. Murphy, Emanuele Rezoagli, Catherine Collins, Sushanta Kumar Saha, Ian Major & Patrick Murray. (2023) Sustainable production and pharmaceutical applications of β-glucan from microbial sources. Microbiological Research 274, pages 127424.
Crossref
Crossref
Lydia Kalafati, Aikaterini Hatzioannou, George Hajishengallis & Triantafyllos Chavakis. (2022) The role of neutrophils in trained immunity. Immunological Reviews 314:1, pages 142-157.
Crossref
Crossref
Xinping Li, Linyue Zhou, Yonghui Yu, Jingjie Zhang, Jing Wang & Baoguo Sun. (2022) The Potential Functions and Mechanisms of Oat on Cancer Prevention: A Review. Journal of Agricultural and Food Chemistry 70:46, pages 14588-14599.
Crossref
Crossref
Anissa S. H. Chan, Takashi O. Kangas, Xiaohong Qiu, Mark T. Uhlik, Ross B. Fulton, Nadine R. Ottoson, Keith B. Gorden, Yumi Yokoyama, Michael E. Danielson, Trinda M. Jevne, Kyle S. Michel, Jeremy R. Graff & Nandita Bose. (2022) Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies. Frontiers in Oncology 12.
Crossref
Crossref
Catarina Caseiro, Joana Nunes Ribeiro Dias, Carlos Mendes Godinho de Andrade Fontes & Pedro Bule. (2022) From Cancer Therapy to Winemaking: The Molecular Structure and Applications of β-Glucans and β-1, 3-Glucanases. International Journal of Molecular Sciences 23:6, pages 3156.
Crossref
Crossref
Jan Spacek, Michal Vocka, Eva Zavadova, Bohuslav Konopasek & Lubos Petruzelka. (2022)
Immunomodulation with β-glucan from
Pleurotus ostreatus
in patients with endocrine-dependent breast cancer
. Immunotherapy 14:1, pages 31-40.
Crossref
Crossref
Emma J. Murphy, Emanuele Rezoagli, Ian Major, Neil J. Rowan & John G. Laffey. (2020) β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application. Journal of Fungi 6:4, pages 356.
Crossref
Crossref
Manuela Del Cornò, Sandra Gessani & Lucia Conti. (2020) Shaping the Innate Immune Response by Dietary Glucans: Any Role in the Control of Cancer?. Cancers 12:1, pages 155.
Crossref
Crossref
Lara Ambrosi, Shaheer Khan, Richard D. Carvajal & Jessica Yang. (2019) Novel Targets for the Treatment of Melanoma. Current Oncology Reports 21:11.
Crossref
Crossref
Nandita Bose, Nadine R. Ottoson, Xiaohong Qiu, Ben Harrison, Jamie R. Lowe, Mark T. Uhlik, Blaine T. Rathmann, Takashi O. Kangas, Lindsay R. Jordan, Kathleen E. Ertelt, Adria Bykowski Jonas, Richard M. Walsh, Anissa S. H. Chan, Ross B. Fulton, Steven M. Leonardo, Kathryn A. Fraser, Keith B. Gorden, Mark A. Matson, Jeremy R. Graff & Richard D. Huhn. (2019) Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers. The Journal of Immunology 202:10, pages 2945-2956.
Crossref
Crossref
Mihai G Netea, Leo A B Joosten & Jos W M van der Meer. (2017) Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. Journal of Leukocyte Biology 102:6, pages 1323-1332.
Crossref
Crossref
Anissa S. H. Chan, Adria Bykowski Jonas, Xiaohong Qiu, Nadine R. Ottoson, Richard M. Walsh, Keith B Gorden, Ben Harrison, Peter J. Maimonis, Steven M. Leonardo, Kathleen E. Ertelt, Michael E. Danielson, Kyle S. Michel, Mariana Nelson, Jeremy R. Graff, Myra L. Patchen & Nandita Bose. (2016) Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. PLOS ONE 11:11, pages e0165909.
Crossref
Crossref
Claire Barton, Kim Vigor, Robert Scott, Paul Jones, Heike Lentfer, Heather J. Bax, Debra H. Josephs, Sophia N. Karagiannis & James F. Spicer. (2016) Beta-glucan contamination of pharmaceutical products: How much should we accept?. Cancer Immunology, Immunotherapy 65:11, pages 1289-1301.
Crossref
Crossref
C. E. Halstenson, T. Shamp, M. A. Gargano, R. M. Walsh & M. L. Patchen. (2016) Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects. Investigational New Drugs 34:2, pages 202-215.
Crossref
Crossref
Clive S. ZentXin Victoria Wang, Rhett P. Ketterling, Curtis A. Hanson, Edward N. Libby, Jacqueline C. Barrientos, Timothy G. Call, Julie E. Chang, Jane J. Liu, Alejandro R. Calvo, Hillard M. Lazarus, Jacob M. Rowe, Selina M. Luger, Mark R. Litzow & Martin S. Tallman. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). American Journal of Hematology 91:3, pages 308-312.
Crossref
Crossref
Petra Langerbeins, Carolin Groß-Ophoff-Müller & Carmen D. Herling. (2016) Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia. Oncology Research and Treatment 39:1-2, pages 18-24.
Crossref
Crossref